Citation map · Study

SZodixStudyAcademic Library

Shelves Open access

Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated

First-line atezolizumab plus chemotherapy in advanced non-squamous non-small cell lung cancer: a cost-effectiveness analysis from China

9 references·1 citing·42 second hop

FromToDepth

this work references cited by second hop

References

2012Model Parameter Estimation and Uncertainty Analysis886 cited
2018A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors320 cited
2011Improved curve fits to summary survival data: application to economic evaluation of health technologies308 cited
2016Health state utilities in non–small cell lung cancer: An international study304 cited
2012Economic Evaluation of First-Line Treatments for Metastatic Renal Cell Carcinoma: A Cost-Effectiveness Analysis in A Health Resource–Limited Setting108 cited
2019First‐line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non–small cell lung cancer: A United States–based cost‐effectiveness analysis105 cited
2019Cost-effectiveness analysis of atezolizumab plus chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer75 cited
2019Cost-effectiveness of Atezolizumab Combination Therapy for First-Line Treatment of Metastatic Nonsquamous Non–Small Cell Lung Cancer in the United States74 cited
2018Cost-effectiveness of afatinib, gefitinib, erlotinib and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China71 cited

Cited by

2021Cost-Effectiveness Analysis of Atezolizumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer With Different PD-L1 Expression Status46 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work